Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/6FCF2E3809D17FD56EDE13EEAF02710641584397ACA20106FEF19A108305247707A3AE9DFB4852FB7BF820FA9D964AB9http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/6FCF2E3809D17FD56EDE13EEAF02710641584397ACA20106FEF19A108305247707A3AE9DFB4852FB7BF820FA9D964AB9http://www.w3.org/2000/01/rdf-schema#comment"Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib."xsd:string
http://purl.uniprot.org/uniprot/#_B669DB1B14BB596351962726BC47B31D10E295D8D162289BF93732E01F74D4AB8B27D522B1B37D7561BD4798B6D0D0F7http://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/6FCF2E3809D17FD56EDE13EEAF02710641584397ACA20106FEF19A108305247707A3AE9DFB4852FB7BF820FA9D964AB9
http://purl.uniprot.org/uniprot/A7E2E0http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/6FCF2E3809D17FD56EDE13EEAF02710641584397ACA20106FEF19A108305247707A3AE9DFB4852FB7BF820FA9D964AB9
http://purl.uniprot.org/uniprot/#_A7E2E0-mappedCitation-26961147http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/6FCF2E3809D17FD56EDE13EEAF02710641584397ACA20106FEF19A108305247707A3AE9DFB4852FB7BF820FA9D964AB9